N-(3-(trifluoromethyl)phenyl)quinazolin-4-amine | 47155-57-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(3-(trifluoromethyl)phenyl)quinazolin-4-amine
• 英文别名: quinazolin-4-yl-(3-trifluoromethylphenyl)-amine；quinazolin-4-yl-(3-trifluoromethyl-phenyl)-amine；N-[3-(trifluoromethyl)phenyl]quinazolin-4-amine
• CAS: 47155-57-7
• 化学式: C₁₅H₁₀F₃N₃
• mdl: MFCD00613074
• 分子量: 289.26
• InChiKey: VCOMYMMMFREKQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-羟基喹唑啉 在 二乙胺 、 三氯氧磷 作用下， 反应 0.42h， 生成 N-(3-(trifluoromethyl)phenyl)quinazolin-4-amine
  参考文献：
  名称：

  微波辅助合成喹啉，异喹啉，喹喔啉和喹唑啉衍生物作为CB2受体激动剂

  摘要：

  使用微波辅助合成法合成喹啉，异喹啉，喹喔啉和喹唑啉衍生物，并使用[ 35 S]GTPγS结合测定法测定其CB1 / CB2受体活性。大部分制备的喹啉，异喹啉和喹喔啉基苯胺均显示出低效的部分CB2受体激动剂活性。最有效的CB2配体是4-吗啉基甲酮衍生物（化合物40e）（-log EC 50  = 7.8；E max  = 75％）。异喹啉-1-基（3-三氟甲基-苯基）胺（化合物26c）是一种高效的CB2激动剂（-log EC 50  = 5.8; E max = 128％）。在这些研究中，没有发现明显的CB1受体激活或失活，除了40e表现出弱的CB1激动剂活性（CB1-log EC 50  = 5.0）。这些配体用作开发选择性CB2受体激动剂的新型模板。

  DOI：

  10.1016/j.bmc.2010.11.059

文献信息

• Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.
  作者：Gordon W. Rewcastle、William A. Denny、Alexander J. Bridges、Hairong Zhou、Donna R. Cody、Amy McMichael、David W. Fry

  DOI：10.1021/jm00018a008

  日期：1995.9

  A series of 4-substituted quinazolines and related compounds have been prepared and evaluated for their ability to inhibit the tyrosine kinase activity of the epidermal growth factor receptor on a phospholipase C-gamma 1-derived substrate. The results show a narrow structure-activity relationship (SAR) for the basic ring system, with quinazoline being the preferred chromophore and benzylamino and anilino

  已经制备了一系列的4-取代的喹唑啉和相关化合物，并评估了它们在磷脂酶C-γ1衍生的底物上抑制表皮生长因子受体的酪氨酸激酶活性的能力。结果表明基本环系统的结构-活性关系（SAR）狭窄，喹唑啉是优选的生色团，苄基氨基和苯胺基是优选的侧链。在4-苯胺基系列中，苯环的3-位被小的亲脂性吸电子基团取代提供了具有增强效价的类似物。研究了两个系列的化合物[4-（苯甲基）氨基和4-（3-溴苯基）氨基]，以确定喹唑啉取代基的SAR。在更具活性的4-（3-溴苯基）氨基系列中，给电子基团（NH2，OMe）在6或7位的活性增加，其模式与对喹唑啉环的8位附近的高电子密度的要求一致。6,7-二甲氧基衍生物是这两个系列中最有效的，而4-（3-溴苯基）氨基衍生物（3）的IC50为0.029 nM，是迄今为止最有效的酪氨酸激酶活性抑制剂。表皮生长因子受体酶的作用。
• Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2)
  作者：Kapil Juvale、Jennifer Gallus、Michael Wiese

  DOI：10.1016/j.bmc.2013.10.007

  日期：2013.12

  Chemotherapy is one of the major forms of cancer treatment. Unfortunately, tumors are prone to multidrug resistance leading to failure of treatment. Breast cancer resistance protein (BCRP), the second member of ABC transporter subfamily G, has been found to play a major role in drug efflux and hence multidrug resistance. Until now, very few potent and selective BCRP inhibitors like Ko143 have been identified. In the search for more potent and selective BCRP inhibitors, we synthesized and investigated a series of differently substituted quinazoline compounds. Several variations at positions 2, 4, 6 and 7 of the quinazoline scaffold were carried out to develop a structure-activity-relationship analysis for these compounds. It was found that compounds bearing a phenyl substituent at position 2 of the 4-anilinoquinazoline scaffold were most potent. On the aniline ring at position 4 of the quinazoline moiety substituents like NO2, CN, CF3 led to very high BCRP inhibition potencies. The most potent compounds were further investigated for their intrinsic cytotoxicity and their ability to reverse the multidrug resistance. Compound 20, an anilinoquinazoline bearing a phenyl ring at position 2 and meta-nitro substitution on the 4-anilino ring, was found to have the highest therapeutic ratio. The most active compounds from each variation were also investigated for their effect on BCRP expression. It was found that compound 20 has no significant effect on BCRP expression, while compound 31 decreased the surface BCRP expression. The only difference in the two compounds was the presence of a 3,4-dimethoxyphenyl ring in compound 31 instead of phenyl substitution at position 2 of the quinazoline moiety. From the study of all target compounds, compound 20 was the most prominent compound having inhibitory potency even higher than Ko143, the most potent BCRP inhibitor known. Compound 20 was also found to be selective towards BCRP with a very high therapeutic ratio. (C) 2013 Elsevier Ltd. All rights reserved.